Australia's most trusted
source of pharma news
Posted 12 May 2024 AM
The TGA waved through a handful of medicines last week, including AFT Pharmaceuticals' tuberculosis treatment and the first generic version of GSK’s nasal spray Avamys.
AFT Pharmaceuticals' Pyrazinamide-AFT, which was accepted for review in September 2023 - roughly 20 months ago - is an anti-tuberculosis agent used in combination with other anti- tuberculosis agents and is commonly used in the first two months of treatment. It has been approved for patients of more than 12 years of age with active drug-sensitive tuberculosis caused by Mycobacterium tuberculosis.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.